Kodiak Sciences (KOD)
(Delayed Data from NSDQ)
$4.76 USD
+0.38 (8.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $4.76 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.76 USD
+0.38 (8.68%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $4.76 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth A Momentum C VGM
Zacks News
Kodiak (KOD) Down as Late-Stage DME Studies Fail
by Zacks Equity Research
Kodiak (KOD) stock plunges as it failed to meet the primary endpoint in phase III studies evaluating tarcocimab in diabetic macular edema patients.
Why Is Kodiak Sciences Inc. (KOD) Up 62.9% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition
by Zacks Equity Research
Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.
Kodiak's (KOD) Q1 Earnings Miss, Pipeline in Focus, Stock Up
by Zacks Equity Research
Despite poor first-quarter performance, Kodiak (KOD) stock rises 13% on the strong pace of the tarcocimab clinical programs.
Why Is Kodiak Sciences Inc. (KOD) Down 26.3% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Immunic's (IMUX) Ulcerative Colitis Study Shows Positive Data
by Zacks Equity Research
Immunic (IMUX) reports positive results from the maintenance phase of the phase II study evaluating its lead candidate, vidofludimus calcium, to treat patients with ulcerative colitis.
Palisade (PALI) Enrolls First Patient in LB1148 Study in China
by Zacks Equity Research
Palisade's (PALI) development partner, Newsoara, enrolls first patient in the late-stage clinical study of LB1148 to improve postoperative GI function for patients in China.
InflaRx (IFRX) Stock Up on FDA's EUA for COVID-19 Treatment
by Zacks Equity Research
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
Kodiak (KOD) Treats First Patient in Diabetic Macular Edema Study
by Zacks Equity Research
Kodiak (KOD) has its first patient in the early-stage study of KSI-501 for treating retinal diseases.
Kodiak Sciences (KOD) Shares are Up 26% in a Week: Here's Why
by Zacks Equity Research
Shares of Kodiak Sciences (KOD) shot up 26% in the last week after the company announced remaining on track with ongoing studies in its fourth-quarter and full-year 2022 earnings report.
Kodiak Sciences Inc. (KOD) Up 1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Does Kodiak Sciences Inc. (KOD) Have the Potential to Rally 87% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 87.4% upside potential for Kodiak Sciences Inc. (KOD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 72% Upside in Kodiak Sciences Inc. (KOD): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 72% upside potential for Kodiak Sciences Inc. (KOD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports a narrower-than-expected loss for the third quarter of 2022. The focus is on the lead candidate, KSI-301, developed for treating various retinal vascular diseases.
Axsome (AXSM) Q3 Loss Narrower Than Expected, Revenues Miss
by Zacks Equity Research
Axsome (AXSM) reports a narrower-than-expected loss in the third quarter. Revenues comprise sales of the sleep drug, Sunosi, acquired from Jazz.
Amicus (FOLD) Q3 Earnings Beat, Galafold Sales Miss Estimates
by Zacks Equity Research
Amicus Therapeutics (FOLD) posts a narrower-than-expected loss in the third quarter. FOLD's sole marketed drug Galafold's solid sales drive the top line.
Intra-Cellular (ITCI) Beat on Q3 Earnings and Sales Estimates
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) posts a narrower-than-expected Q3 loss and sales also beat the mark. ITCI continues to advance its pipeline with developmental programs.
Agios (AGIO) Q3 Loss Narrower Than Expected, Sales Miss
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts narrower-than-expected Q3 loss while sales miss estimates. The company is enrolling participants across five pivotal studies evaluating the lead drug Pyrukynd.
Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y
by Zacks Equity Research
Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.
Ultragenyx's (RARE) Q3 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Ultragenyx (RARE) reports a wider-than-expected loss in the third quarter. Revenues, though up year over year, miss estimates.
Repligen (RGEN) Beats Q3 Earnings Estimate, Ups 2022 Guidance
by Zacks Equity Research
Repligen (RGEN) reports encouraging third-quarter results, with sales and earnings beating estimates. RGEN also raises its financial guidance for 2022
Why Is Kodiak Sciences Inc. (KOD) Down 23.8% Since Last Earnings Report?
by Zacks Equity Research
Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kodiak Sciences (KOD) Rises 60% in Past 3 Months: Here's Why
by Zacks Equity Research
Kodiak Sciences (KOD) has progressed well with the development of its lead pipeline candidate, tarcocimab, for treating various retinal vascular diseases.
Kodiak Sciences (KOD) Focuses on Developing Eye Drug Tarcocimab
by Zacks Equity Research
Kodiak Sciences (KOD) lead pipeline candidate, tarcocimab, being developed for treating various retinal vascular diseases, holds potential. Stiff competition in the market remains a woe.
Kodiak Sciences (KOD) Q2 Earnings Beat, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports narrower-than-expected loss for the second quarter of 2022. The focus is on the lead candidate, KSI-301, which is being developed for treating various retinal vascular diseases.